Skip to main content Skip to section navigation Skip to footer
SCYNEXIS, Inc. SCYNEXIS, Inc.
  • About Us
    • Our Mission
    • Leadership
    • Partnerships
    • Careers
    • Contact Us
  • Our Science
    • Ibrexafungerp
    • Life-threatening Infections
    • Community Infections
    • Pipeline
    • Publications and Presentations
  • Our Product
  • News
    • News
    • Events
  • Careers
  • Investors
    • News & Events
    • Company Info
    • Financial Info
    • Stock Info
    • SEC Filings
    • Governance

Press Releases

Investors

Investors

  • Overview
  • News & Events
    • Overview
    • Press Releases
    • IR Calendar
    • Presentations
    • Email Alerts
  • Company Info
    • Overview
    • Leadership
    • Contacts
    • FAQ
    • Tear Sheet
  • Financial Info
    • Overview
    • Financial Results
    • Key Ratios
    • Investor Calculator
  • Stock Info
    • Quote
    • Charts
    • Historical Data
    • Analyst Coverage
    • Investor Calculator
  • SEC Filings
    • Overview
    • All SEC Filings
    • Annual Filings
    • Quarterly Filings
  • Governance
    • Overview
    • Board of Directors
    • Board Committees
    • Governance Documents
  • News & Events

  • Overview
  • Press Releases
  • IR Calendar
  • Presentations
  • Email Alerts
Dec 19, 2011 9:00am EST

MMV and SCYNEXIS Offer 400 Active Compounds for Neglected Disease Drug Research at No Cost

Jul 12, 2011 8:20am EDT

Innovative Vector Control Consortium Announces Discovery Project With SCYNEXIS

Jun 16, 2011 8:15am EDT

SCYNEXIS and TB Alliance Sign HEOS Software Agreement

Mar 28, 2011 8:15am EDT

Dr. Dennis Schmatz Joins SCYNEXIS as Strategic Advisor

Nov 11, 2010 12:00pm EST

SCYNEXIS Receives Four Grants Under Federal Therapeutic Discovery Project Program

Nov 10, 2010 8:30am EST

SCYNEXIS Introduces Application for Mobile Access to HEOS Information System

Nov 09, 2010 8:00am EST

SCYNEXIS Receives Merial Research Collaboration Milestone Payment

Sep 14, 2010 8:52am EDT

SCYNEXIS Announces Presentations of Data From Anti-Fungal Drug Candidate at the 50th ICAAC Meeting

May 19, 2010 8:08am EDT

SCYNEXIS and Trevena Announce Strategic Collaboration to Enhance Discovery of Biased GPCR Ligands

Apr 16, 2010 9:35am EDT

SCYNEXIS Presents In Vitro Toxicity Study Suggesting that SCY-635 is Unique in the Cyclophilin Inhibitor Class

  • Previous Pagearrow_back
  • Page 1
  • …
  • Page 26
  • Page 27
  • Page 28
  • Page 29
  • Page 30
  • Page 31
  • Page 32
  • Page 33
  • Page 34
  • Page 35
  • Next Pagearrow_forward
rss_feed News RSS
  • Email Alerts
  • Company Profile
  • Contacts
  • RSS News Feed
Scynexis
1 Evertrust Plaza, Jersey City, NJ 07302
(201) 884-5485
Facebook Twitter Linkedin
  • Patents
  • Expanded Access
  • Privacy Policy
  • Disclaimer
  • Sitemap
© 2025 SCYNEXIS, Inc. All Rights Reserved.